纤维溶解药物诱导出血:机制和解决方案
Mingqing Tang1, Chengjia Hu, Hongjun Lin
1Medicine School, Huaqiao University, Quanzhou, Fujian, China.
概括
新型纤维溶解药物通过不依赖患者的等离子体产生,比传统的血栓溶解药物提供了更好的疗效和安全性. 研究总结了减轻出血风险的机制和解决方案,以确保更安全的药物开发.
科学领域:
- 生物医学研究的研究.
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
背景情况:
- 血栓形成是一个重大的全球健康威胁,增加了死亡率和并发症,特别是在COVID-19后.
- 传统的血栓抑制药物,如血原激活剂,由于患者的血原水平有所限制.
- 纤维溶解药物代表了具有直接作用机制的有希望的替代品.
研究的目的:
- 系统地审查纤维溶解药物的分子机制.
- 识别和总结与纤维溶解药物治疗相关的减轻出血风险的解决方案.
- 为开发更安全,更有效的纤维素溶解剂提供见解.
主要方法:
- 系统的文献审查纤维溶解药物研究的最新进展.
- 分析纤维素分解和出血背后的分子机制.
- 综合当前的战略,以提高纤维溶解药物的安全性.
主要成果:
- 与等离子体激活剂相比,纤维溶解药物显示出更高的疗效和安全性,这是由于它们与内源性等离子体激活剂的独立性.
- 出血风险仍然是一个主要问题,需要进一步调查其分子基础.
- 已确定的策略为提高新型纤维解毒剂的安全性提供了潜在的途径.
结论:
- 纤维溶解药物具有显著的潜力,可提高治疗血栓的疗效.
- 解决出血风险对于这些新型药物的临床转化至关重要.
- 未来的研究应该通过更深入地了解它们的机制和降低风险的策略,专注于开发更安全的纤维溶解药物.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
763
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
763
01:16Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:05Introduction to Hemostasis
8.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.4K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K